Media coverage about Amphastar Pharmaceuticals (NASDAQ:AMPH) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amphastar Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the company an impact score of 42.9679594012183 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
A number of brokerages have recently commented on AMPH. Piper Jaffray Companies set a $19.00 target price on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, October 22nd. BidaskClub cut shares of Amphastar Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 9th. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Needham & Company LLC lifted their target price on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a report on Friday, December 1st. Finally, Jefferies Group set a $19.00 target price on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, October 29th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $19.50.
Amphastar Pharmaceuticals (AMPH) opened at $18.78 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86. The stock has a market cap of $863.42, a price-to-earnings ratio of 123.73, a price-to-earnings-growth ratio of 1.30 and a beta of 1.69. Amphastar Pharmaceuticals has a 12 month low of $12.05 and a 12 month high of $19.95.
In other Amphastar Pharmaceuticals news, Director Stephen B. Shohet sold 7,862 shares of the business’s stock in a transaction on Thursday, October 19th. The shares were sold at an average price of $18.34, for a total transaction of $144,189.08. Following the sale, the director now directly owns 31,978 shares in the company, valued at approximately $586,476.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William J. Peters sold 6,226 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $19.67, for a total transaction of $122,465.42. The disclosure for this sale can be found here. Insiders sold a total of 80,649 shares of company stock worth $1,503,873 over the last three months. 11.10% of the stock is currently owned by corporate insiders.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.